Phase II trial of oral carmofur in advanced pancreatic carcinoma

Ann Oncol. 1991 Nov-Dec;2(10):765-6. doi: 10.1093/oxfordjournals.annonc.a057861.

Abstract

Thirty-one patients with advanced carcinoma of the pancreas and with no prior exposure to chemotherapy were treated with HCFU. This drug was administered orally at a dose of 300-500 mg/m2 in 6-week cycles with a 2-week interval between the cycles. One partial response was observed and 7 patients showed stable disease. The median survival of the 31 patients was 8.3 +/- 5.4 months (range 1.3-20.3 months). The toxicity was moderate.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / surgery

Substances

  • Antineoplastic Agents
  • carmofur
  • Fluorouracil